Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128680) titled 'Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: City of Hope Medical Center
Condition:
Advanced Clear Cell Renal Cell Carcinoma
Advanced Sarcomatoid Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Metastatic Sarcomatoid Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
I...